Pacific Biosciences CFO sells 661,815 shares

One-quarter of the option shares vested on the grant's one-year anniversary; the balance vests monthly over the next three years if service continues.

Rhea-AI Filing Summary

Pacific Biosciences of California, Inc. (PACB) Chief Financial Officer James R. Gibson II exercised options covering 500,000 shares on October 6, 2026, at an exercise price of $1.18 per share, acquiring 500,000 common shares. His reported option position afterward was 1,500,000 shares.

That day, he sold 661,815 shares at a weighted average price of $3.108 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026, and prices ranged from $3.00 to $3.33 per share.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Gibson James R II

Role See Remarks

Sold 661,815 shs ($2.06M)

Approx. gross sale proceeds $2.06M

Approx. exercise cost $590K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F3	500,000	$0.00	$0.00
Exercise	Common Stock	500,000	$1.18	$590K
Sale	Common Stock F1, F2	661,815	$3.108	$2.06M

Holdings After Transaction: Stock Option (right to buy) — 1,500,000 contracts (Direct); Common Stock — 1,083,848 shares (Direct)

Footnotes (3)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
2. F2. This sale price represents the weighted average sale price of the shares sold ranging from $3.00 to $3.33 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. F3. 1/4th of the shares subject to the option vested on the one year anniversary of the date of grant, and the balance of shares vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date.

Key Figures

Options exercised: 500,000 shares Exercise price: $1.18 per share Common shares acquired: 500,000 shares +4 more

7 metrics

Options exercised 500,000 shares October 6, 2026

Exercise price $1.18 per share Options exercised October 6, 2026

Common shares acquired 500,000 shares October 6, 2026

Shares sold 661,815 shares October 6, 2026

Weighted average sale price $3.108 per share Shares sold October 6, 2026

Sale price range $3.00 to $3.33 per share Shares sold October 6, 2026

Reported option position after exercise 1,500,000 shares Following the October 6, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, vested, exercise price

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"weighted average sale price of the shares sold"

vested technical

"shares subject to the option vested on the one year anniversary"

exercise price financial

"options exercised at an exercise price of $1.18 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PACB shares did James R. Gibson II sell, and at what price?

James R. Gibson II sold 661,815 shares on October 6, 2026, at a weighted average price of $3.108 per share. The sale prices ranged from $3.00 to $3.33 per share, and the sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026.

How many PACB options did the chief financial officer exercise?

James R. Gibson II exercised options covering 500,000 shares at $1.18 per share on October 6, 2026, acquiring 500,000 common shares. His reported option position afterward was 1,500,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/08/2026 - 04:08 PM Accepted by SEC EDGAR 10/08/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gibson James R II

(Last) (First) (Middle)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

1305 O'BRIEN DRIVE

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2026		M		500,000	A	$1.18	1,745,663	D
Common Stock	10/06/2026		S(1)		661,815	D	$3.108(2)	1,083,848	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.18	10/06/2026		M			500,000	03/31/2026(3)	03/31/2035	Common Stock	500,000	$0	1,500,000	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.

2. This sale price represents the weighted average sale price of the shares sold ranging from $3.00 to $3.33 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. 1/4th of the shares subject to the option vested on the one year anniversary of the date of grant, and the balance of shares vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date.

Remarks:

Chief Financial Officer

	/s/ Brett Atkins, Attorney-in-fact	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)